Seegene introduces a High-throughput 8-plex Test for Flu A, Flu B, RSV and COVID-19 with dual internal controls
SEOUL, South Korea, Sept. 8, 2020 /PRNewswire/ -- Seegene, Inc. introduced a single tube real-time RT-PCR assay, Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay, which simultaneously detects and differentiates Flu A, Flu B, RSV A/B, and three different target genes of COVID-19 (S gene, RdRP gene and N ge...
Seegene introduces a High-throughput 8-plex Test for Flu A, Flu B, RSV and COVID-19 with dual internal controls
SEOUL, South Korea, Sept. 8, 2020 /PRNewswire/ -- Seegene, Inc. introduced a single tube real-time RT-PCR assay, Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay, which simultaneously detects and differentiates Flu A, Flu B, RSV A/B, and three different target genes of COVID-19 (S gene, RdRP gene and N ge...
Seegene Allplex(TM) 2019-nCoV Assay (SARS-CoV-2) Gets Expanded FDA Emergency Use Authorization
SEOUL, South Korea, July 30, 2020 /PRNewswire/ -- Seegene, Inc. announced that U.S. Food and Drug Administration (FDA) has further expanded the emergency use authorization (EUA) for its Allplex™ 2019-nCoV Assay, a real-time RT-PCR test for SARS-CoV-2, the novel coronavirus responsible for the COV...
Seegene Exports 10 million Corona Tests to Brazil
SEOUL, Korea, May 18, 2020 /PRNewswire/ -- Seegene Inc. (096530.KQ), a leading developer of multiplex PCR technologies headquartered inSouth Korea, announced that it will export 10 million tests of its COVID-19 testing kits to Pan American Health Organization (PAHO) / World Health Organization (W...
Seegene's Allplex™ 2019-nCoV Assay receives FDA Emergency Use Authorization
SEOUL, South Korea, April 22, 2020 /PRNewswire/ -- Seegene, Inc. announced that U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for its Allplex™ 2019-nCoV Assay, a Real-time RT-PCR test for SARS-CoV-2, the novel coronavirus responsible for the COVID-19 disease. ...
Seegene exported 10 Million COVID-19 Diagnostic Tests to Over 60 countries
SEOUL, South Korea, April 20, 2020 /PRNewswire/ -- Seegene, Inc., the leading multiplex diagnostic assay developer, today announced that the company has exported over 10 million tests of Allplex™ 2019-nCoV Assay to over 60 countries, which accounts for a significant portion of globally performed ...
Seegene exported 10 Million COVID-19 Diagnostic Tests to Over 60 countries
SEOUL, South Korea, April 20, 2020 /PRNewswire/ -- Seegene, Inc., the leading multiplex diagnostic assay developer, today announced that the company has exported over 10 million tests of Allplex™ 2019-nCoV Assay to over 60 countries, which accounts for a significant portion of globally performed ...
Seegene Receives Health Canada Approval for its COVID-19 Assay
SEOUL, South Korea, April 13, 2020 /PRNewswire/ -- Seegene, Inc. announced that Health Canada (HC) authorized an interim order which allows the import and sale inCanada of Seegene's Allplex™ 2019-nCoV Assay, a Real-time RT-PCR test for SARS-CoV-2, the novel coronavirus responsible for the COVI...
Seegene launches KFDA Approved COVID-19 Assay
SEOUL, South Korea, Feb. 18, 2020 /PRNewswire/ -- Korea Centers for Disease Control & Prevention notified Seegene Inc. (096530.KQ) that Korea Ministry of Food and Drug Safety (MFDS; Former KFDA) approved its novel coronavirus (COIVD-19) Real-time PCR assay for the Emergency Use, following the rec...
Seegene Highlights Clinical Automated Nucleic Acid Extraction System at ASM Microbe 2019
SEOUL, South Korea, June 21, 2019 /PRNewswire/ -- Seegene Inc. (096530.KQ), a leading developer of multiplex PCR technologies headquartered inSouth Korea, announced that it has completed the FDA registration of its nucleic acid extraction instrument, the Seegene STARlet, and will begin offering t...
Seegene Establishes Brazilian Subsidiary
SEOUL, South Korea, June 18, 2019 /PRNewswire/ -- Seegene Inc. (096530.KQ), a leading developer of multiplex PCR technologies headquartered inSouth Korea, announced today the formation of a new subsidiary, Seegene do Brasil Diagnosticos Ltda., inBelo Horizonte, Brazil. Seegene do Brasil Diagnos...
Seegene launches a new anti-microbial drug resistance test kit, replacing the conventional culture method
SEOUL, South Korea, Nov. 26, 2018 /PRNewswire/ -- Seegene Inc. (096530.KQ), a leading developer of multiplex PCR assays, announced that multi-site clinical trials for measuring clinical performance on screening the drug resistance of Enterobacteriaceae with the Allplex™ Entero-DR assay have been ...
Seegene Unveils New Real-time PCR Analysis Technology, Drastically Increasing Its Multiplexing Capacity
SEOUL, South Korea, Sept. 19, 2018 /PRNewswire/ -- Seegene Inc. (096530.KQ), a leading developer of multiplex PCR technologies, today announced its proprietary technology, "MuCT™". This is a real-time PCR based data acquiring and analyzing technology that increases its multiplexing capability per...
Seegene Will Unveil Combination Test at ECCMID 2018
SEOUL, South Korea, April 17, 2018 /PRNewswire/ -- Seegene Inc. (096530.KQ), a leading developer of multiplex PCR technologies, announced that it will attend the 28th European Congress of Clinical Microbiology and Infectious Diseases ("ECCMID 2018") taking place inMadrid, Spain, from April 21 to ...
Seegene develops world's first multiplex MDx assays with its AI system
SEOUL, South Korea, Jan. 3, 2018 /PRNewswire/ -- Seegene Inc. (096530.KQ), a leading developer of multiplex PCR technologies headquartered inSouth Korea, announced today that, utilizing a newly created artificial intelligence ("AI") based assay development system, the company succeeded in develop...
Unique concept of MDx, Seegene Random Access System, announced at AACC 2017
SEOUL, South Korea, July 26, 2017 /PRNewswire/ -- Seegene Inc. (096530.KQ), the world's leading developer of multiplex molecular diagnostics technologies and assays, is to present its unique Seegene Random Access System (the "System") at the 69th AACC Annual Clinical Lab Expo in San Diego, CA,...
Seegene enters the U.S. diagnostic market in collaboration with Thermo Fisher Scientific
SEOUL, South Korea, May 22, 2017 /PRNewswire/ -- Seegene Inc. (096530.KQ), the world's leading developer of multiplex molecular diagnostics technologies and assays, today announced that it has entered into a new strategic collaboration relationship with Thermo Fisher Scientific in which Seegene w...
Seegene enters the U.S. diagnostic market in collaboration with Thermo Fisher Scientific
SEOUL, South Korea, May 22, 2017 /PRNewswire/ -- Seegene Inc. (096530.KQ), the world's leading developer of multiplex molecular diagnostics technologies and assays, today announced that it has entered into a new strategic collaboration relationship with Thermo Fisher Scientific in which Seegene w...
Seegene Unlocks the Door to the Next Level of the Real-time PCR Business
SEOUL, South Korea, April 26, 2017 /PRNewswire/ -- Seegene Inc. (096530.KQ), the leading developer of multiplex PCR technologies, announced that it is entering into more innovative and powerful business realm by developing the Second-generation Real-time PCR Technology which has been recently pat...
Seegene to Introduce Automated Development of in silico-based Multiplex Real-time PCR Assays
SEOUL, South Korea, Aug. 3, 2016 /PRNewswire/ -- Seegene, Inc. (096530.KQ), a leading developer of multiplex real-time PCR technologies announced that it has introduced the world's first automated development ofin silico-based multiplex real-time PCR assays. Real-time PCR is the best method for ...
